Pharmacy - Pharmacoeconomics News & Articles

461 Advances in Cancer Therapeutics and Patient Access to New Drugs PharmacoEconomics, March 4, 2011

462 Value of Information in the Osteoarthritis Setting: Cost Effectiveness of COX-2 Selective Inhibitors, Traditional NSAIDs and Proton Pump Inhibitors PharmacoEconomics, March 4, 2011

463 Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children: A Review PharmacoEconomics, March 4, 2011    Review Article

464 Posaconazole: A Pharmacoeconomic Review of its Use in the Prophylaxis of Invasive Fungal Disease in Immunocompromised Hosts PharmacoEconomics, March 4, 2011

465 Comparing Methods of Data Synthesis: Re-Estimating Parameters of an Existing Probabilistic Cost-Effectiveness Model PharmacoEconomics, March 4, 2011

466 Sample Size and Power for Cost-Effectiveness Analysis PharmacoEconomics, March 3, 2011

467 Effectiveness and Cost Effectiveness of Expanding Harm Reduction and Antiretroviral Therapy in a Mixed HIV Epidemic: A Modeling Analysis for Ukraine Full Text PLoS Medicine, March 3, 2011

468 Cost-effectiveness of Endodontic Molar Retreatment Compared with Fixed Partial Dentures and Single-tooth Implant Alternatives Journal of Endodontics, March 2, 2011

469 Dabigatran may be a cost-effective alternative to warfarin for stroke prevention in atrial fibrillation Full Text Formulary , February 24, 2011

470 Cost Utility of Prostate Cancer Chemoprevention with Dutasteride in Men with an Elevated Prostate Specific Antigen Cancer Prevention Research, February 22, 2011

471 Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care European Journal of Clinical Investigation, February 18, 2011

472 Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention Full Text JAMA Internal Medicine, February 17, 2011    Clinical Article

473 Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations PharmacoEconomics, February 14, 2011

474 Economic Costs of Nonmedical Use of Prescription Opioids The Clinical Journal of Pain, February 14, 2011

475 Drug Burden Index and Beers Criteria: Impact on Functional Outcomes in Older People Living in Self-Care Retirement Villages The Journal of Clinical Pharmacology, February 11, 2011

476 Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value International Journal of Technology Assessment in Health Care, February 11, 2011

477 An Economic Comparison of Three Cell Culture Techniques: Fed-Batch, Concentrated Fed-Batch, and Concentrated Perfusion Full Text BioPharm International, February 10, 2011

478 Registering New Drugs for Low-Income Countries: The African Challenge Full Text PLoS Medicine, February 9, 2011

479 The social and economic consequences of epilepsy: A controlled national study Full Text Epilepsia, February 8, 2011

480 High-Value, Cost-Conscious Health Care: Concepts for Clinicians to Evaluate the Benefits, Harms, and Costs of Medical Interventions Full Text Annals of Internal Medicine, February 7, 2011

1 Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement Clinical Therapeutics, April 18, 2013    Review Article

2 The Economic Burden of Treatment-Resistant Depression Clinical Therapeutics, April 19, 2013

3 Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact Journal of Clinical Pharmacy and Therapeutics, April 10, 2013    Review Article

4 Review of Economics and Cost-Effectiveness Analyses of Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation in the US Annals of Pharmacotherapy, April 22, 2013    Review Article

5 Role of the Pharmacist in Achieving Performance Measures to Improve the Prevention and Treatment of Venous Thromboembolism Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, April 9, 2013

6 A systematic review and meta-analysis of pharmacist-led fee-for-services medication review British Journal of Clinical Pharmacology, April 24, 2013    Evidence Based Medicine    Review Article

7 Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation Clinical Cardiology, March 18, 2013    Free full text

8 Cost-effectiveness of deep brain stimulation in patients with Parkinsons disease Movement Disorders, April 29, 2013

9 Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany Clinical Research in Cardiology, March 27, 2013

10 Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer Annals of Oncology, March 26, 2013

11 The Cost-Effectiveness of Oral Direct Factor Xa Inhibitors Compared with Low-Molecular-Weight Heparin for the Prevention of Venous Thromboembolism Prophylaxis in Total Hip or Knee Replacement Surgery Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, April 29, 2013

12 Cost effectiveness analysis of elementary school-located vaccination against influenza-Results from a randomized controlled trial Vaccine , March 20, 2013

13 Projecting future drug expenditures in U.S. nonfederal hospitals and clinics--2013 American Journal of Health-System Pharmacy, March 13, 2013    Review Article

14 Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies Bone Marrow Transplantation, April 16, 2013

15 Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations- A simulation of comparative cost-effectiveness British Journal of Cancer, April 15, 2013    Review Article

16 Systematic Review and Quality Assessment of Cost-Effectiveness Analysis of Pharmaceutical Therapies for Advanced Colorectal Cancer Annals of Pharmacotherapy, April 8, 2013    Evidence Based Medicine    Review Article

17 Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer Colorectal Disease, April 2, 2013

18 The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions Multiple Sclerosis Journal, April 22, 2009

19 Economic Evaluation of Fulvestrant 500 mg Versus Generic Nonsteroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer in the United Kingdom Clinical Therapeutics, March 26, 2013

20 Outcomes, Health Costs and Use of Antiplatelet Agents in 7,082 Patients Admitted for an Acute Coronary Syndrome Occurring in a Large Community Setting Cardiovascular Drugs and Therapy, March 28, 2013